Zacks Investment Research downgraded shares of VBI Vaccines, Inc. (NASDAQ:VBIV) from a hold rating to a sell rating in a research note issued to investors on Tuesday, August 1st.
According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “
VBIV has been the subject of several other reports. ValuEngine upgraded shares of VBI Vaccines from a sell rating to a hold rating in a report on Wednesday, July 12th. Noble Financial restated a buy rating on shares of VBI Vaccines in a report on Monday, May 15th. Finally, TheStreet lowered shares of VBI Vaccines from a c- rating to a d+ rating in a report on Wednesday, May 31st. Two analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $5.38.
In other news, CEO Jeff Baxter purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $3.28 per share, for a total transaction of $32,800.00. Following the purchase, the chief executive officer now directly owns 110,255 shares in the company, valued at approximately $361,636.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 54.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new stake in VBI Vaccines during the second quarter valued at approximately $167,000. Schwab Charles Investment Management Inc. acquired a new stake in VBI Vaccines during the second quarter valued at approximately $187,000. Bank of New York Mellon Corp acquired a new stake in VBI Vaccines during the second quarter valued at approximately $193,000. Teachers Advisors LLC acquired a new stake in VBI Vaccines during the second quarter valued at approximately $195,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in VBI Vaccines during the second quarter valued at approximately $262,000. Institutional investors and hedge funds own 29.49% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about VBI Vaccines Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VBI Vaccines Inc. and related companies.